PPARG and cancer: Recently, it has been evidenced thatthiazolidinedione, a new class of antidiabetic as a specific ligand for PPAR-γ,and retinoic receptor agonists can regulate differentiation of cancer cells [24],and that nuclear-actingprostanoids, including 15-d-PGJ2, are potent activators of the PPAR-γreceptor isoform [25, 26].